ABSTRACT
This review gives concise information on green technology (GT) and Industrial Revolution 4.0 (IR 4.0). Climate change has begun showing its impacts on the environment, and the change is real. The devastating COVID-19 pandemic has negatively affected lives and the world from the deadly consequences at a social, economic, and environmental level. In order to balance this crisis, there is a need to transition toward green, sustainable forms of living and practices. We need green innovative technologies (GTI) and Internet of Things (IoT) technologies to develop green, durable, biodegradable, and eco-friendly products for a sustainable future. GTI encompasses all innovations that contribute to developing significant products, services, or processes that lower environmental harm, impact, and worsening while augmenting natural resource utilization. Sensors are typically used in IoT environmental monitoring applications to aid ecological safety by nursing air or water quality, atmospheric or soil conditions, and even monitoring species' movements and habitats. The industries and the governments are working together, have come up with solutions-the Green New Deal, carbon pricing, use of bio-based products as biopesticides, in biopharmaceuticals, green building materials, bio-based membrane filters for removing pollutants, bioenergy, biofuels and are essential for the green recovery of world economies. Environmental biotechnology, Green Chemical Engineering, more bio-based materials to separate pollutants, and product engineering of advanced materials and environmental economies are discussed here to pave the way toward the Sustainable Development Goals (SDGs) set by the UN and achieve the much-needed IR 4.0 for a greener-balanced environment and a sustainable future.
ABSTRACT
We evaluated the diagnostic utility of flow cytometry immunophenotyping in bone marrow aspirates and peripheral blood, in the assessment of mature B-cell non-Hodgkin lymphoma (MBNHL). We analyzed 356 cases of MBNHL received for immunophenotyping over a 4 year period. All cases were reviewed, correlated with biopsy specimen (lymph node and splenectomy). Discrepant cases were re-evaluated. Common subtypes included chronic lymphocytic leukemia (CLL) (243 cases, 68.5%), follicular lymphoma (30 cases, 8.5%), mantle cell lymphoma (20 cases, 5.5%), splenic marginal zone lymphoma (18 cases, 5%), hairy cell leukemia (18 cases, 5%). CD5+/CD23+ had a high positive predictive value (PPV) for diagnosing CLL whereas CD5+/CD23- had a high negative predictive value (NPV) for diagnosing mantle-cell lymphoma (MCL). Limited panel of 9 antibodies mainly CD19, CD5, CD23, CD10, FMC7, kappa, lambda, CD3 and CD20 help diagnose more than 92% of cases of MBNHL. Minimal diagnostic panels become important in countries with limited resources.
